Sanjay Kaul, Abdulla Damluji, Dr Shariq Shamim, Dr. Purvi Parwani, and Anu Lala highlight CHIP-BCIS3 and related Impella studies as negative or concerning, citing a neutral win ratio and mortality signals.
CHIP-BCIS3: Another Impella Trial bites the dust
win ratio 0.85 (no benefit signal)
Mortality concern — higher CV death with Impella (HR 1.91)
Higher all cause death in Impella (statistically not significant). WOW.
Impella CP + intentional 30-min PCI delay vs. immediate PCI
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare